Sandoz Says All Options Still Open After Spinoff Rumors
Unconfirmed Report Suggested Novartis Was Favoring Separate Listing Over Sale
Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.
